New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

The investigational dual GLP-1 and amylin receptor agonist Amycretin demonstrated significant weight loss-up to 24% with ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Novo Nordisk (NVO) says its novel obesity drug, amycretin, shows promising results with up to 24% of weight loss in a Phase 1/2 trial. Read more here.

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was published in The Lancet and presented at the American ...

Once-weekly amycretin, a novel peptide activating GLP-1, amylin, and calcitonin receptors, produced rapid, substantial, and sustained weight loss in adults with overweight or obesity during a ...

Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to target appetite regulation, were published in ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the Danish drugmaker can improve on the data that triggered a jump in ...

Novo Nordisk, the Danish pharmaceutical company behind amycretin — and also the maker of Wegovy and Ozempic — hopes the pill version of amycretin could make weight-loss therapy more accessible ...